Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 2Phase 3 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 131Thoracic 52Head & Neck 26Genitourinary 14Lymphoid 11Gynecologic 11Other solid neoplasm 9Breast 9Dermatologic 6CNS 6Tumor-Agnostic 3Sarcoma 2Other hematologic neoplasm 2Myeloid 1

Conditions

Neoplasms 2Adenocarcinoma 1

Interventions

Gemcitabine 26Paclitaxel 24pembrolizumab 23Carboplatin 22Bevacizumab 18Radiotherapy 16Oxaliplatin 16Erlotinib Hydrochloride 16Nivolumab 15Cisplatin 14Capecitabine 14Fluorouracil 13Trastuzumab 12Docetaxel 12atezolizumab 11Magnetic Resonance Spectroscopy 11Leucovorin 11Cyclophosphamide 11Irinotecan 10Ipilimumab 10Vemurafenib 9Everolimus 9Cetuximab 9cabozantinib 8Radiosurgery 8Afatinib 8130-nm albumin-bound paclitaxel 8trametinib 7lenvatinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × tislelizumab × Tumor-Agnostic × Clear all
NCT06238752 2024-02-02

RENMIN-213

Renmin Hospital of Wuhan University

Phase 2 Completed
33 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT04985721 2023-03-15

IMPARP-HRD

Peter MacCallum Cancer Centre, Australia

Phase 2 Unknown
60 enrolled
Tumor-Agnostic

Neoplasms

NCT05241132 2022-02-15

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Shanghai Changzheng Hospital

Phase 2 Unknown
27 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡